Surveillance of invasive pneumococcal disease in Europe, 2010
In 2010, a new enhanced surveillance system for invasive pneumococcal disease was established in the European Union, coordinated by ECDC, and this report describes the results of the first year of data collection (2010 data). The main aim is to provide information on the epidemiological trends and morbidity caused by the circulating S. pneumoniae serotypes, antimicrobial susceptibility and certain other epidemiological features of invasive pneumococcal disease.
Invasive bacterial diseases - Annual Epidemiological Report 2014 [2012 data]
This report presents the epidemiological situation for vaccine-preventable diseases – invasive bacterial diseases (invasive Haemophilus influenzae, meningococcal and pneumococcal disease) as of 2012 and describes the statistical and epidemiological methods used.
External quality assessment scheme for Streptococcus pneumoniae – 2014
In July 2014, a panel of three strains of Streptococcus pneumoniae and two simulated samples of cerebrospinal fluid was sent to 30 reference laboratories in the IBD-labnet surveillance network for quality assessment testing. This report summarises the diagnostic results submitted by the participating laboratories.
Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
Pneumococcal meningitis in French children before and after the introduction of pneumococcal conjugate vaccineArchived
In the context of an active nationwide surveillance network, this study describes pneumoccocal meningitis in children aged from 1 day to 15 years during a 8 year study period (2001-2008) in France. 951 pneumoccocal meningitis cases were reported among 3312 children with bacterial meningitis. T
Serotype replacement in disease after pneumococcal vaccinationArchived
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.